Clinical trial NCT02181699: Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Official title: Phase 1 Study of KHK2823 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome
Lead sponsor: Kyowa Kirin Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2014-07-04
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a first in human, non-randomized, open-label, dose escalation study to investigate the safety, pharmacokinetics, immunogenicity and pharmacodynamics of repeat doses of KHK2823.

Detailed description: This is a Phase 1, multi-center, open-label, dose-escalation study of KHK2823 in adult patients with previously untreated AML who are not candidates for intensive remission induction therapy; relapsed/refractory AML for whom no other standard therapy is available or appropriate; or relapsed/refractory MDS who have received prior therapy with a hypomethylating agent, such as decitabine and azacitidine or who are not candidates to receive a hypomethylating agent, this would include high risk or transfusion-dependent low risk patients. Patients must have documented primary or secondary AML or MDS according to World Health Organization (WHO) criteria. Following the provision of signed informed consent, patients will be screened for entry into the study. The study consists of 2 parts. In Part 1, 3 to 6 patients per cohort will be enrolled sequentially in up to 7 dose-escalation cohorts to establish the MTD. KHK2823 will be administered once weekly. In Part 2, up to an additional 18 patients may be enrolled to further evaluate the safety, PK, PD, potential anti-leukemic activity of KHK2823.

Eligibility criteria: Inclusion Criteria:

* Males and females ≥ 18 years old with previously untreated AML who are not candidates for intensive remission induction therapy; relapsed/refractory AML for whom no other standard therapy is available or appropriate; or relapsed/refractory MDS who have received prior therapy with a hypomethylating agent or who are not candidates to receive a hypomethylating agent
* Histopathologically/cytologically documented primary or secondary AML, as defined by WHO criteria, or MDS, confirmed by pathology review at treating institution
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
* Life expectancy of at least 3 months

Exclusion Criteria:

* Histological diagnosis of acute promyelocytic leukemia (FAB Type M3)
* Clinically significant central nervous system leukemia
* Treatment of the underlying hematologic condition with systemic therapy during the treatment period, including any chemotherapy, radiation or investigational therapy, within 2 weeks prior to KHK2823 administration; or immunotherapy within 30 days prior to KHK2823 administration; with the exception of hydroxyurea (Hydrea®) for treatment of hyperleukocytosis, which must be discontinued at least 24 hours prior to the first dose of KHK2823

Primary outcomes:
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability.
timeFrame: Assessed weekly for duration of treatment (anticipated minimum 8 weeks), plus 42 day follow up period
Secondary outcomes:
measure: Pharmacokinetics: Peak serum concentration (Cmax) Time to reach Cmax (tmax) Minimum serum concentration (Ctrough) Area under curve (AUC) Half-life (t1/2) Clearance (CL) Volume of distribution (Vd) Accumulation ratio (R)
timeFrame: Assessed during first 24 weeks of treatment, plus 42 day follow up period
measure: Disease Response: overall response rate (ORR), overall survival (OS), event-free survival (EFS), relapse-free survival (RFS), progression-free survival (PFS) and disease-free survival (DFS)
timeFrame: Assessed every 8 weeks for duration of treatment (anticipated minimum 8 weeks), plus 14 day follow up period
measure: Immunogenicity: anti-KHK2823 antibody
timeFrame: Assessed every 4 weeks for first 24 weeks of treatment, plus 42 day follow up period
measure: Pharmacodynamics: CD123+
timeFrame: Assessed during first 24 weeks of treatment, plus 42 day follow up period
Other outcomes:
Locations:
city: Brighton
country: United Kingdom
facility: University of Sussex, Royal Sussex County Hospital
city: Glasgow
country: United Kingdom
facility: Beatson West of Scotland Cancer Centre
city: Leeds
country: United Kingdom
facility: St James's Institute of Oncology
city: London
country: United Kingdom
facility: NIHR/Wellcome UCLH Clinical Research Facility University College Hospital London
city: London
country: United Kingdom
facility: St Bartholomew's Hospital
city: Newcastle Upon Tyne
country: United Kingdom
facility: Northern Centre for Cancer Care, Freeman Road Hospital
city: Southampton
country: United Kingdom
facility: Southampton General Hospital
Study officials:
References: